SteadyMed Therapeutics
SteadyMed aspires to redefine the parenteral therapeutics experience for patients dependent upon large doses of intravenous and subcutaneous medications.
Launch date
Employees
Market cap
-
Enterprise valuation
$216m (Public information from Apr 2018)
Rehovot Center District (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$2.0m | Series A | ||
| N/A | $10.4m | Early VC | |
$3.0m | Debt | ||
| N/A | $19.6m | Late VC | |
| N/A | $40.0m Valuation: $160m | IPO | |
$32.0m | Post IPO Equity | ||
$30.0m | Post IPO Equity | ||
* | $216m Valuation: $216m | Acquisition | |
| Total Funding | $32.0m | ||
Related Content
Recent News about SteadyMed Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.